P037 Elexacaftor/tezacaftor/ivacaftor improve lung disease in patients with advanced cystic fibrosis homozygous for the F508del mutation.
Saved in:
| Title: | P037 Elexacaftor/tezacaftor/ivacaftor improve lung disease in patients with advanced cystic fibrosis homozygous for the F508del mutation. |
|---|---|
| Authors: | Carnovale, V. (AUTHOR), Iacotucci, P. (AUTHOR), Terlizzi, V. (AUTHOR), Colangelo, C. (AUTHOR), Medio, P. (AUTHOR), Ferrillo, L. (AUTHOR), De Gregorio, F. (AUTHOR), Francalanci, M. (AUTHOR), Taccetti, G. (AUTHOR), Buonaurio, S. (AUTHOR), d'Ippolito, M. (AUTHOR), Marsicovetere, G. (AUTHOR), D'Andria, M. (AUTHOR), Ferrara, N. (AUTHOR), Salvatore, D. (AUTHOR) |
| Source: | Journal of Cystic Fibrosis. 2021 Supplement, Vol. 20, pS49-S50. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 15691993 |
|---|---|
| DOI: | 10.1016/S1569-1993(21)01064-X |
